Literature DB >> 35235030

Liposomal bupivacaine nerve block provides better pain control post-total shoulder arthroplasty than continuous indwelling catheter.

Ryan Krupp1, Austin Smith2, John Nyland3, Colton Mojesky4, Deandrea Perkins4, Leah Y Carreon5.   

Abstract

BACKGROUND: Pain control is essential to successful total shoulder arthroplasty (TSA).
MATERIALS AND METHODS: This non-blinded, randomized clinical trial compared shoulder pain, narcotic use, interscalene (IS) block application time, and costs in 76 subjects who were randomly assigned to receive either a single injection IS nerve block of 10 cc (133 mg) liposomal bupivacaine mixed with 10 cc of 0.5% bupivacaine (Group 1), or 20 cc of 0.5% ropivacaine direct injection combined with an indwelling IS nerve block catheter delivering 0.2% ropivacaine at a continual 4 cc/h infusion for the initial 3 post-operative days (Group 2). Surgical time, local anesthesia duration, hospital stay length, morphine milligram equivalents (MME) consumed, worst shoulder pain at 24, 48 and 72 h, and complications were recorded. Patient reported function, pain and activity level surveys were completed before, and 6-week post-TSA (P < 0.05).
RESULTS: Group 1 had less pain 24-h (0.72 ± 0.8 vs. 3.4 ± 2.9, p < 0.0001) and 48-h (2.5 ± 2.2 vs. 4.8 ± 2.6, p = 0.005) post-TSA. At 24-h post-TSA, MME consumption was similar (Group 1 = 4.5 ± 6.4 vs. Group 2 = 3.7 ± 3.8, p = 0.54), but was lower for Group 1 at 48 h (0.0 ± 0.0 vs. 0.64 ± 0.99, p = 0.001). Group 2 had longer IS block application time (10.00 ± 4.6 min vs. 4.84 ± 2.7 min, p < 0.0001). Only group 2 had a strong relationship between MME consumption over the first 24-h post-TSA and pain 24-h post-TSA (r = 0.76, p < 0.0001), a moderate relationship with pain 48-h post-TSA (r = 0.59, P = 0.001), and a weak relationship with pain 72-h post-TSA (r = 0.44, P = 0.02). Significant relationships for these variables were not observed for Group 1 (r ≤ 0.30, p ≥ 0.23). Group 1 IS block costs were less/patient than Group 2 ($190.17 vs. $357.12 USD).
CONCLUSION: A single shot, liposomal bupivacaine interscalene nerve block provided better post-TSA pain control with less narcotic consumption, less time for administration and less healthcare system cost compared to interscalene nerve block using a continuous indwelling catheter. LEVEL OF EVIDENCE: Level I, Prospective, Randomized.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Opioid consumption; Pain management; Post-surgical treatment

Year:  2022        PMID: 35235030     DOI: 10.1007/s00402-022-04386-5

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  44 in total

1.  Local infiltration analgesia versus continuous interscalene brachial plexus block for shoulder replacement pain: a randomized clinical trial.

Authors:  Karen T Bjørnholdt; Jan M Jensen; Thomas F Bendtsen; Kjeld Søballe; Lone Nikolajsen
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-08-15

Review 2.  Efficacy of liposomal bupivacaine in shoulder surgery: a systematic review and meta-analysis.

Authors:  Oluwadamilola Kolade; Karan Patel; Rivka Ihejirika; Daniel Press; Scott Friedlander; Timothy Roberts; Andrew S Rokito; Mandeep S Virk
Journal:  J Shoulder Elbow Surg       Date:  2019-07-16       Impact factor: 3.019

3.  What Pain Levels Do TSA Patients Experience When Given a Long-acting Nerve Block and Multimodal Analgesia?

Authors:  Jacques T YaDeau; David M Dines; Spencer S Liu; Michael A Gordon; Enrique A Goytizolo; Yi Lin; Aaron A Schweitzer; Kara G Fields; Lawrence V Gulotta
Journal:  Clin Orthop Relat Res       Date:  2019-03       Impact factor: 4.176

4.  Interscalene regional anesthesia for shoulder surgery.

Authors:  Julie Y Bishop; Mark Sprague; Jonathan Gelber; Marina Krol; Meg A Rosenblatt; James Gladstone; Evan L Flatow
Journal:  J Bone Joint Surg Am       Date:  2005-05       Impact factor: 5.284

5.  A 3-arm randomized clinical trial comparing interscalene blockade techniques with local infiltration analgesia for total shoulder arthroplasty.

Authors:  Jason K Panchamia; Adam W Amundson; Adam K Jacob; Hans P Sviggum; Ngoc Tram V Nguyen; Joaquin Sanchez-Sotelo; John W Sperling; Darrell R Schroeder; Sandra L Kopp; Rebecca L Johnson
Journal:  J Shoulder Elbow Surg       Date:  2019-07-26       Impact factor: 3.019

6.  Liposomal bupivacaine infiltration in the surgical site for analgesia after rotator cuff repair: a randomized, double-blinded, placebo-controlled trial.

Authors:  Nicole M Verdecchia; Mark W Rodosky; Michael Kentor; Steven L Orebaugh
Journal:  J Shoulder Elbow Surg       Date:  2020-12-05       Impact factor: 3.019

7.  Randomized Controlled Trial of Interscalene Block Compared with Injectable Liposomal Bupivacaine in Shoulder Arthroplasty.

Authors:  Surena Namdari; Thema Nicholson; Joseph Abboud; Mark Lazarus; Dean Steinberg; Gerald Williams
Journal:  J Bone Joint Surg Am       Date:  2017-04-05       Impact factor: 5.284

8.  A Prospective Evaluation of Opioid Utilization After Upper-Extremity Surgical Procedures: Identifying Consumption Patterns and Determining Prescribing Guidelines.

Authors:  Nayoung Kim; Jonas L Matzon; Jack Abboudi; Christopher Jones; William Kirkpatrick; Charles F Leinberry; Frederic E Liss; Kevin F Lutsky; Mark L Wang; Mitchell Maltenfort; Asif M Ilyas
Journal:  J Bone Joint Surg Am       Date:  2016-10-19       Impact factor: 5.284

9.  Outcomes after resection arthroplasty versus permanent antibiotic spacer for salvage treatment of shoulder periprosthetic joint infections: a systematic review and meta-analysis.

Authors:  Michelle Xiao; Adam J Money; W Michael Pullen; Emilie V Cheung; Geoffrey D Abrams; Michael T Freehill
Journal:  J Shoulder Elbow Surg       Date:  2021-11-10       Impact factor: 3.019

10.  Liposomal bupivacaine: a review of a new bupivacaine formulation.

Authors:  Praveen Chahar; Kenneth C Cummings
Journal:  J Pain Res       Date:  2012-08-14       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.